Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

NCT05380271 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG: sequential DEB-BACE and Arotinib and Tirelizumab
DRUG: DEB-BACE alone

Sponsor

Gang Wu